Promoters influence the kinetics of transgene expression following adenovector gene delivery

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 123-131

  Chen, Ping ^a   Tian, Jie ^a,b   Kovesdi, Imre ^a,c   Bruder, Joseph T ^a  

^a GENVEC INC   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c VectorLogics Inc   (United States)

Author keywords

Adenovirus; Gene delivery; Gene therapy; Promoters; Vectors

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE; NEUTRALIZING ANTIBODY; VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VIVO STUDY; KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ROUS SARCOMA ONCOVIRUS; SKELETAL MUSCLE; TRANSGENE; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL LINE; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPETENCE; INJECTIONS, INTRAVENOUS; KINETICS; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MUSCLE, SKELETAL; PROMOTER REGIONS (GENETICS); ROUS SARCOMA VIRUS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; ANIMALIA; CYTOMEGALOVIRUS; MUS; ROUS SARCOMA VIRUS;

EID: 39449114547     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1127     Document Type: Article

References (38)

1. Anton R, Kordower JH, Maidment NT, et al. Neural-targeted gene therapy for rodent and primate herniparkinsonism. Exp Neurol 1994; 127: 207-218.
2. Yang Y, Xiang Z, Ertl HC, et al. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995; 92: 7257-7261.
3. Yang Y, Li Q, Ertl HC, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
4. Engelhardt JF, Ye X, Doranz B, et al. Ablation of E2A in recombinant adenoviruses improves transgene. Proc Natl Acad Sci U S A 1994; 91: 6196-6200.
5. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1415.
6. Tripathy SK, Goldwasser E, Lu M-M, et al. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci U S A 1994; 91: 11557-11561.
7. Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2: 545-550.
8. Wadsworth SC, Zhou H, Smith AE, et al. Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J Virol 1997; 71: 5189-5196.
9. Svensson EC, Black HB, Dogger DL, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 1997; 8: 1797-1806.
10. Guo ZS, Wang LH, Eisensmith RC, et al. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
11. Zabner J, Wadsworth SC, Smith AE, et al. Adenovirus-mediated generation of cAMP-stimulated Cl- transport in cystic fibrosis airway epithelia in vitro: effect of promoter and administration method. Gene Ther 1996; 3: 458-465.
12. Dai Y, Roman M, Naviaux RK, et al. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A 1992; 89: 10892-10895.
13. Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther 1995; 6: 1291-1297.
14. Bruder JT, Jie T, McVey DL, et al. Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol 1997; 71: 7623-7628.
15. Muruve DA ' Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
16. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003; 10: 935-940.
17. Philpott NJ, Nociari M, Elkon KB, et al. Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Natl Acad Sci U S A 2004; 101: 6200-6205.
18. Ritter T, Brandt C, Prosch S, et al. Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine 2000; 12: 1163-1170.
19. Qin L, Ding Y, Pahud DR, et al. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
20. Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-77.
21. Chinnadurai G, Chinnadurai S, Brusca J. Physical mapping of a large-plaque mutation of adenovirus type 2. J Virol 1979; 32: 623-628.
22. Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
23. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
24. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564-2570.
25. Yang Y, Jooss KU, Su Q, et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-144.
26. Chen P, Kovesdi I, Bruder JT. Effective repeat administration with adenovirus vectors to the muscle. Gene Ther 2000; 7: 587-595.
27. Perrin LA, June JE, Rosebury W, et al. Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121). Gene Ther 2004; 11: 512-521.
28. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-4411.
29. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-1781.
30. De Geest B, Van Linthout S, Lox M, et al. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101-112.
31. Hauser MA, Robinson A, Hartigan-O'Connor D, et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2000; 2: 16-25.
32. Jooss K, Yang Y, Fisher KJ, et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
33. Chen HH, Mack LM, Choi SY, et al. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999; 10: 365-373.
34. Ferrari G, Salvatori G, Rossi C, et al. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 1995; 6: 733-742.
35. Sung RS, Qin L, Bromberg JS. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression. Mol Ther 2001; 3: 757-767.
36. Larochelle N, Lochmuller H, Zhao J, et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/ enhancer. Gene Ther 1997; 4: 465-472.
37. Johnson JE, Wold BJ, Hauschka SD. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol Cell Biol 1989; 9: 3393-3399.
38. van Deutekom JCT, Floyd SS, Booth DK, et al. Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul Disord 1998; 8: 135-148.